简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
29
2024-04
Notice of Annual General Meeting
29
2024-04
(1) 2023 Report of The Board of Directors (2) 2023 Report of The Board of Supervisors (3) 2023 Annual Report (4) Proposed Re-Election of Directors of The Second Session of The Board (5) Proposed Re-Election of Shareholder Representative Supervisors of The
29
2024-04
2023 Environmental, Social and Governance Report
29
2024-04
Annual Report 2023
12
2024-04
Loan Facility
08
2024-04
Voluntary Announcement Phase 3 Clinical Trial Completed in China for Aflibercept Intravitreous Injection (BA9101) and BLA to be Filed
08
2024-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
25
2024-03
Annual Results Announcement for the Year Ended 31 December 2023
12
2024-03
Notice of Board Meeting
08
2024-03
Voluntary Announcement Phase 3 Clinical Trial Completed in China for Dulaglutide Injection (BA5101) and BLA to be Filed
3
4
5
6
7
Follow me
鲁公网安备37069102000284